Merck & Co., Inc. (MRK)
Merck (MRK) Q3 Earnings and Revenues Top Estimates
Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago.
Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year
Merck CEO Robert Davis joins 'Squawk Box' to discuss the company's quarterly earnings results, which topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business, the company's drug pipeline outlook, and more.
Merck tops estimates despite muted Gardasil and diabetes drug sales
Merck & Co Inc (NYSE:MRK, ETR:6MK) has topped third-quarter estimates despite flagging sales of its Gardasil jab, diabetes drugs and Covid-19 treatment. Revenue for the three months to September climbed by 4% to $16.66 billion, the pharmaceutical firm reported on Thursday, ahead of market expectations for $16.46 billion.
Merck tops earnings estimates on strong demand for Keytruda even as HPV vaccine sales fall
CNBC's Becky Quick reports on the company's quarterly earnings results.
Merck's Q3 earnings beat estimates, but company lowers guidance
Merck's stock swung between gains and losses in premarket action.
Merck third quarter better than expected, but Gardasil sales sag in China again
Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the U.S. drugmaker also flagged a second straight quarter of weak demand for its Gardasil vaccine in China.
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.
Merck's Earnings Need to Reassure Investors That All Is Well
The drug company had a disastrous second quarter. It doesn't want a repeat performance.
Exploring Analyst Estimates for Merck (MRK) Q3 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key drugs Gardasil and Winrevair. Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement.
Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?
Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
